Dysmenorrhea Treatment Market (2026 - 2035)
월경통 치료 시장 조사 보고서 - 2032년까지의 글로벌 예측.
Forecast Period
2026-2035
CAGR
8.35%
2025 Market Size
USD 5.31 Billion
2035 Market Size
USD 11.83 Billion
Dysmenorrhea Treatment Market 요약
Dysmenorrhea Treatment Market 시장의 주요 기업은 다음과 같습니다
향후 전망
Dysmenorrhea Treatment Market 향후 전망
보고서 범위
| Parameter | Detail |
| Market Scope | Global market for pharmaceutical and hormonal therapies indicated for primary and secondary dysmenorrhea, spanning prescription and over-the-counter channels |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 8.35% (2026–2035) |
| Market Size Checkpoints | USD 5.31 Billion (2025); USD 5.75 Billion (2026); USD 7.92 Billion (2030); USD 11.83 Billion (2035) |
| Fastest Growing Segments | Hormonal Therapy (by Treatment Type); Secondary Dysmenorrhea (by Type); Online Pharmacies (by Distribution Channel) |
| Companies Profiled | Bayer AG, Pfizer Inc., Kenvue Inc., Haleon plc, Reckitt Benckiser Group, AbbVie Inc., Organon & Co., Sumitomo Pharma, Teva Pharmaceutical Industries, Viatris Inc., Gedeon Richter |
| Valuation Currency | USD Billion (constant 2025 dollars) |
시장 하이라이트
FAQs
What should procurement teams weigh when tendering supply for the Dysmenorrhea Treatment Market?
Prioritise suppliers with dual-site API sourcing for naproxen and ibuprofen. Lock 24-month pricing where possible, because generic price compression reverses sharply during shortage events. [Ref 11]
How do OTC and prescription channels differ in margin structure?
OTC brands hold 45–60% gross margins on shelf presence and brand equity. Prescription hormonal products carry higher per-unit revenue but face payer rebates and prior-authorisation friction that compress net realisation to roughly 30–38%. [Ref 7]
Which entry route works best for new companies in the Dysmenorrhea Treatment Market?
Repurposing approved molecules through abbreviated regulatory pathways cuts development timelines by three to five years. Novel chemical entities rarely justify the cost against entrenched generic competition. [Ref 25]
What integration challenges arise with digital therapeutic adjuncts?
Reimbursement codes remain inconsistent across payers and clinical validation standards vary by regulator. Successful launches pair the application with an existing prescription product rather than selling it standalone. [Ref 9]
Does patent cliff exposure threaten valuations in the Dysmenorrhea Treatment Market?
Only marginally. Most revenue already sits in off-patent products, so exclusivity risk concentrates in GnRH antagonists with protection running into the early 2030s. [Ref 3]
What regulatory nuance matters for cross-border e-pharmacy distribution?
Hormonal products require in-market prescription validation, which blocks most cross-border models. Regulators in Brazil and India have tightened online dispensing, pushing platforms toward licensed domestic partnerships. [Ref 17]
Which emerging use case deserves the closest watch?
Adolescent-specific formulations — lower-dose, faster-onset presentations designed for school-age patients. Pediatric labelling extensions offer exclusivity value alongside a defensible clinical position no incumbent currently holds. [Ref 6]
저자
Author
Rahul Gotadki
Co-Author
Nidhi Mandole
공유:
Secondary Research
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO) Global Health Observatory, National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), American College of Obstetricians and Gynecologists (ACOG), Royal College of Obstetricians and Gynaecologists (RCOG), International Federation of Gynecology and Obstetrics (FIGO), American Society of Reproductive Medicine (ASRM), European Society of Human Reproduction and Embryology (ESHRE), Office on Women's Health (OWH), National Health Service (NHS) England, Organisation for Economic Co-operation and Development (OECD) Health Statistics, World Bank Health, Nutrition and Population Statistics, IQVIA Institute for Human Data Science, IMS Health (IQVIA) Pharmaceutical Market Data, Global Burden of Disease Study (IHME), and national health ministry reports from key markets including the US, UK, Germany, France, Japan, China, and India. These sources were used to collect epidemiological data on primary and secondary dysmenorrhea prevalence, regulatory approval data for pain relievers (NSAIDs, COX-2 inhibitors), hormonal therapies (oral contraceptives, GnRH agonists), and surgical interventions, clinical safety studies, demographic trends, treatment guidelines, and market landscape analysis across North America, Europe, Asia-Pacific, and Rest of World.
Primary Research
In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, heads of regulatory affairs, and commercial directors from pharmaceutical companies that specialize in pain management medications, hormonal therapy manufacturers, and women's health medicines were examples of supply-side sources. Board-certified obstetricians and gynecologists, reproductive medicine specialists, doctors who treat pain, hospital pharmacy directors, medical directors of women's health clinics, and procurement leads from hospitals, gynecology clinics, fertility centers, and academic medical centers were among the demand-side sources. Primary research obtained information on clinical adoption patterns, pricing strategies, reimbursement dynamics, and patient compliance rates. It also verified product pipeline timelines for novel non-hormonal and hormonal therapies and validated market segmentation across primary dysmenorrhea and secondary dysmenorrhea categories.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)
By Region: North America (38%), Europe (29%), Asia-Pacific (28%), Rest of World (5%)
Market Size Estimation
Global market valuation was derived through revenue mapping and treatment volume analysis across pain relievers, hormonal therapy, and surgical segments. The methodology included:
Identification of 35+ key pharmaceutical manufacturers and medical device companies across North America, Europe, Asia-Pacific, and Latin America specializing in dysmenorrhea therapeutics
Product mapping across NSAIDs (ibuprofen, naproxen, mefenamic acid), hormonal therapies (combined oral contraceptives, progestins, GnRH agonists, levonorgestrel IUDs), and surgical interventions (laparoscopy, hysterectomy)
Analysis of reported and modeled annual revenues specific to dysmenorrhea and women's health portfolios
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (treatment volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for primary dysmenorrhea and secondary dysmenorrhea treatment markets
공유:
무료 샘플 다운로드
이 보고서의 무료 샘플을 받으려면 아래 양식을 작성하십시오
공유:
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
Guilherme Gomes Martins
Product Management Director
사례 연구
Aerospace & Defense
